Correlation between DNA Ploidy,
Proliferation Marker Ki-67 and Early
Tumor Progression in Renal Cell
Carcinoma

Papadopoulos, I.; Weichert-Jacobsen, K.; Wacker, Hans‐Heinrich; Sprenger, E

doi:10.1159/000474417

Cited by 10 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of the tumour proliferation marker Ki-S5 was found to correlate with survival. This is in contrast to reported findings regarding the expression of another proliferation marker, the Ki-67 antigen, and of the tumour suppressor p53 as prognostic indicators in RCC [13][14][15]. The p53 gene does not play a major role in development of RCC, whereas in early events of tumorigenesis high expression of c-neu and c-fos oncogenes, and proto-oncogene bcl-2, inhibitor of apoptosis, is detected [16][17].…”

Section: Diagnostic and Prognostic Biomarkers For Rcccontrasting

confidence: 89%

Contribution of proteomics to the molecular analysis of renal cell carcinoma with an emphasis on manganese superoxide dismutase

et al. 2001

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) originates in the renal cortex. It accounts for 2-3 percent of all cancers occurring in adults and it is characterised by lack of early clinical manifestations, unpredictable outcome, and absence of effective treatment modalities except early surgery. RCC comprises a heterogeneous group of tumours with various molecular and cytogenetic abnormalities and different histological features as cell types and tumour architecture. Molecular genetic and proteomic tools led to the discovery of potential diagnostic prognostic and therapeutic biomarkers of RCC. In this review we discuss recent developments in understanding genotype-phenotype relationships, with attention to manganese superoxide dismutase, a mitochondrial enzyme related to the redox cycle which affects various regulatory functions of cells. The expression of this protein has been evaluated in numerous human tumour types including RCC, and post-translational modifications are being investigated.

show abstract

Section: Diagnostic and Prognostic Biomarkers For Rcccontrasting

confidence: 89%

Contribution of proteomics to the molecular analysis of renal cell carcinoma with an emphasis on manganese superoxide dismutase

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Subsequently, it was shown that Ki‐67 immunolabeling with various antibodies is an efficient parameter for separating patients with RCC into groups with significantly different prognoses, as described previously 2, 39. In our analysis using a Cox multivariate regression model, Ki‐67 indexing did not reach statistical significance 18, 40, 42–44…”

Section: Discussionsupporting

confidence: 50%

“…Other studies have used different Ki‐67 antibodies, such as MIB‐141 and Ki‐67,42 for RCC immunohistochemistry. None of those antibodies were helpful as prognostic markers for disease outcome.…”

Section: Discussionmentioning

confidence: 99%

The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma

Lehmann

Retz

Nürnberg

et al. 2004

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND The American Joint Committee on Cancer and the Union Internationale Contre le Cancer have acknowledged routine laboratory parameters, such as serum calcium, alkaline phosphatase, hemoglobin, and the erythrocyte sedimentation rate (ESR), as predictors of survival in patients with renal cell carcinoma. The predictive value of these parameters compared with proliferation markers, such as Ki‐67, proliferating cell nuclear antigen (PCNA), topoisomerase II‐α, and p100, has not been determined. METHODS Forty‐eight consecutive patients who underwent nephrectomy for nonmetastatic renal cell carcinoma between 1990 and 1994 were observed up to 120 months postoperatively. Ten of 48 patients developed tumor progression 6–69 months after surgery. Routine preoperative laboratory parameters as well as tumor‐specific data were assessed. Findings were compared with tumor proliferation indices, which were obtained by immunohistochemical staining for nuclear antigens Ki‐67, PCNA, topoisomerase II‐α, and p100 in paraffin embedded tumor tissue. RESULTS Univariate and multivariate statistical analyses demonstrated superiority of routine laboratory values compared with tumor proliferation indices in predicting progression‐free survival and disease‐specific death. The best predictor after tumor size and symptomatic presentation was ESR (P < 0.0001), with ESR values > 70 mm at 2 hours indicating a significantly poorer prognosis. Only the proliferation marker Ki‐67 reached univariate significance at a threshold of 7%. CONCLUSIONS Routine laboratory parameters, such as alkaline phosphatase, lactate dehydrogenase, thrombocyte count, and especially ESR, provided superior long‐term prognostic information for patients with nonmetastatic renal cell carcinoma compared with the molecular tumor proliferation markers Ki‐67, PCNA, topoisomerase II‐α, and p100. Cancer 2004. © 2004 American Cancer Society.

show abstract

“…Numerous studies on DNA analysis of RCC have been published during the last decade. The prognostic value of DI has been investigated, and patients with aneuploid DNA tumors are considered to be at high risk of disease progression and death due to disease 9, 15, 18–23. In some of these studies, mention was made of the presence of more than one nondiploid cell population,8, 9, 24 discordance between DNA ploidy pattern of the primary tumor and its metastases,25 and the presence of both diploid and nondiploid cell populations within the same tumor 9, 26, 27.…”

Section: Discussionmentioning

confidence: 99%

Intratumoral heterogeneity of DNA content in renal cell carcinoma and its prognostic significance

Ruiz-Cerdá

Hernández

Sempere

et al. 1999

Cancer

View full text Add to dashboard Cite

BACKGROUND A multiple sampling study was performed on 124 specimens of renal cell carcinomas to analyze the consistency and reliability of DNA measurements. The authors investigated intratumoral DNA heterogeneity and its role as a adverse prognostic factor for disease progression. METHODS DNA content was analyzed by flow cytometry on three different samples of the same tumor. The Cronbach α coefficient was used to assess the reliability and a Cox proportional hazards model was used to test the effect of DNA ploidy heterogeneity on time of disease progression. RESULTS The agreement among the DNA ploidy samples was high. The number of aneuploid findings increased significantly with the number of samples analyzed. The presence of non‐diploid cell populations was a significant adverse predictive value for disease progression. However, the authors were unable to demonstrate that intratumoral heterogeneity DNA content had any influence on the biological behavior of the tumor. CONCLUSIONS Determination of DNA ploidy based on single samples may be inaccurate. Spatial variation in DNA ploidy is a feature of renal cell carcinoma; however, its biologic significance remains to be demonstrated. Cancer 1999;86:664–71. © 1999 American Cancer Society.

show abstract

Correlation between DNA Ploidy, Proliferation Marker Ki-67 and Early Tumor Progression in Renal Cell Carcinoma

Cited by 10 publications

References 14 publications

Contribution of proteomics to the molecular analysis of renal cell carcinoma with an emphasis on manganese superoxide dismutase

Contribution of proteomics to the molecular analysis of renal cell carcinoma with an emphasis on manganese superoxide dismutase

The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma

Intratumoral heterogeneity of DNA content in renal cell carcinoma and its prognostic significance

Contact Info

Product

Resources

About